1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Saved in:
| Title: | 1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT) |
|---|---|
| Authors: | Galvao, V.1 (AUTHOR), Palomero, J.2 (AUTHOR), Creus-Gonzalez, I.2 (AUTHOR), Lostes Bardaji, M.J.3 (AUTHOR), Lozano-Rabella, M.4 (AUTHOR), Garcia-Garijo, A.2 (AUTHOR), Yuste, A.4 (AUTHOR), Rodriguez, L.5 (AUTHOR), Villalobos Alberú, X.6 (AUTHOR), Rotxes, M.7 (AUTHOR), Vieito Villar, M.8 (AUTHOR), Saavedra Santa Gadea, O.3 (AUTHOR), Alonso, G.9 (AUTHOR), Braña, I.3 (AUTHOR), Muñoz-Couselo, E.10 (AUTHOR), Querol, S.5 (AUTHOR), Tabernero, J.11 (AUTHOR), Martín-Lluesma, S.12 (AUTHOR), Gros, A.13 (AUTHOR), Garralda, E.9 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS650-S650. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2977 |
